Biotech IV Monitor

PTGX — Protagonist Therapeutics Inc.

$8.8B market cap · 0 upcoming readouts tracked

Clinical trial readout dates for Protagonist Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced.

Market cap$8.8B
Cash & investments$835Mas of Sep 30, 2026
Recent 8-K filings1latest 2026-11-05

In progress, no date published

Phase 3 Icotrokinra
Psoriatic Arthritis
date not published
Trial Planned
Phase 2 PN-235 (JNJ-77242113)
Inflammatory bowel diseases (IBD)
date not published
Trial Planned
Phase 2 Rusfertide (PTG-300)
Hereditary hemochromatosis
date not published
Trial Planned

Cash position

Protagonist Therapeutics Inc. reported $835M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-06). It reported net income of $220M for that quarter.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-05

Companies working on similar indications

Discussion

No messages yet. If you follow PTGX, you can start the conversation.
Track PTGX in real time
See live implied volatility for PTGX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on PTGX
Contact — questions or corrections about PTGX: dukeupt@gmail.com